P. Vlachostergios

发表

Treatment resistance in urothelial carcinoma: an evolutionary perspective

P. Vlachostergios, B. Faltas, Panagiotis J. Vlachostergios, 2018, Nature Reviews Clinical Oncology.

The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 1: post-translational regulation

P. Vlachostergios, D. Daliani, A. Patrikidou, 2009, Journal of cellular and molecular medicine.

Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner

P. Vlachostergios, C. Papandreou, C. Befani, 2013, Investigational New Drugs.

Antibody therapeutics for treating prostate cancer: where are we now and what comes next?

P. Vlachostergios, S. Tagawa, Beerinder S. Karir, 2017, Expert opinion on biological therapy.

The ubiquitin-proteasome system in glioma cell cycle control

P. Vlachostergios, I. Voutsadakis, C. Papandreou, 2012, Cell Division.

Nonbacterial Thrombotic (Marantic) Endocarditis in a Patient with Colorectal Cancer

P. Vlachostergios, D. Daliani, I. Voutsadakis, 2010, Oncology Research and Treatment.

Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer

P. Vlachostergios, D. Daliani, C. Papandreou, 2012, Journal of Negative Results in BioMedicine.

Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer

N. Bander, J. Osborne, P. Christos, 2021, The Prostate.

Common germline-somatic variant interactions in advanced urothelial cancer

W. Chung, M. Rubin, O. Elemento, 2020, Nature Communications.

Evidence of association between methylenetetrahydrofolate reductase gene and susceptibility to breast cancer: a candidate-gene association study in a South-eastern European population.

G. Bakalos, P. Vlachostergios, E. Zintzaras, 2012, DNA and cell biology.

The interplay of cell cycle and DNA repair gene alterations in upper tract urothelial carcinoma: predictive and prognostic implications

P. Vlachostergios, 2020, Precision clinical medicine.

Feasibility of Energy Medicine in a Community Teaching Hospital: An Exploratory Case Series

P. Vlachostergios, Jill Blakeway, K. Julliard, 2015, Journal of alternative and complementary medicine.

Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells

P. Vlachostergios, I. Voutsadakis, A. Patrikidou, 2012, Cancer Cell International.

Pilot study of the diagnostic utility of 89Zr‐df‐IAB2M and 68Ga‐PSMA‐11 PET imaging and multiparametric MRI in localized prostate cancer

D. Margolis, N. Bander, J. Osborne, 2022, The Prostate.

Baseline Insulin-Like Growth Factor-I Plasma Levels, Systemic Inflammation, Weight Loss and Clinical Outcome in Metastatic Non-Small Cell Lung Cancer Patients

Sunita Ghosh, V. Baracos, P. Vlachostergios, 2011, Oncology.

Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis.

D. Mavroudis, V. Georgoulias, Sunita Ghosh, 2011, Lung cancer.

Baseline Plasma Levels of Interleukin-8 in Stage IV Non-Small-Cell Lung Cancer Patients: Relationship With Nutritional Status and Prognosis

K. Kitikidou, D. Mavroudis, V. Georgoulias, 2012, Nutrition and cancer.

Basic Concepts in Metastatic Cardiac Disease

P. Vlachostergios, D. Daliani, C. Papandreou, 2012, Cardiology research.

Molecular Targeted Therapies of Prostate Cancer

P. Vlachostergios, A. Molina, M. Paddock, 2018 .

Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer

N. Agarwal, O. Smaletz, E. Antonarakis, 2021, JCO precision oncology.

Trimodality therapy in variant urothelial carcinoma: choose wisely

P. Vlachostergios, S. Tagawa, C. Jakubowski, 2017, Translational andrology and urology.

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

S. Vallabhajosula, N. Bander, C. Sternberg, 2020 .

CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.

N. Agarwal, E. Antonarakis, C. Sternberg, 2020, JCO precision oncology.

Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

S. Vallabhajosula, N. Bander, C. Sternberg, 2020 .

Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)

H. Beltran, S. Vallabhajosula, N. Bander, 2019, Annals of Oncology.

Abstract 4865: Prognostic value of BRCA2 and AR gene alterations in advanced prostate cancer patients treated with PSMA-targeted radionuclide therapies

O. Elemento, H. Beltran, N. Bander, 2019, Clinical Research (Excluding Clinical Trials).

Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).

N. Bander, J. Osborne, P. Christos, 2019, Journal of Clinical Oncology.

Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.

O. Elemento, A. Sboner, H. Beltran, 2019, Journal of Clinical Oncology.

Combined DNA repair defects in testicular metastasis from prostate cancer sensitize to immune checkpoint blockade

P. Vlachostergios, 2021, Current urology.

Exceptional Response to Pembrolizumab in a Patient With Castration-Resistant Prostate Cancer With Pancytopenia From Myelophthisis.

H. Beltran, P. Vlachostergios, S. Tagawa, 2019, Journal of oncology practice.

Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma

Ioannis A Tamposis, P. Vlachostergios, I. Mitsogiannis, 2022, Journal of kidney cancer and VHL.

Bevacizumab in advanced cervical cancer

P. Vlachostergios, C. Papandreou, 2014, Clinical and Translational Oncology.

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer

David A. Green, P. Kantoff, M. Morris, 2022, JNCI cancer spectrum.

Systemic Therapies for Patients with Metastatic Spinal Disease

A. Saxena, P. Vlachostergios, 2020 .

Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells

P. Vlachostergios, D. Daliani, I. Voutsadakis, 2011, Cancer Cell International.

The Endothelin Axis in DNA Damage and Repair: The Cancer Paradigm

P. Vlachostergios, C. Papandreou, 2013 .

Selecting for predisposition to cancer cachexia

P. Vlachostergios, C. Papandreou, I. Gioulbasanis, 2012, EMBO molecular medicine.

Biomarkers in Prostate-Specific Membrane Antigen Theranostics

P. Vlachostergios, I. Zachos, V. Tzortzis, 2021, Diagnostics.

Abiraterone survival benefit is independent of pain, prostate-specific antigen and Gleason sum in men with chemo-naïve metastatic castration-resistant prostate cancer (analysis of COU-AA-302)

P. Vlachostergios, S. Tagawa, G. Galletti, 2018 .

p53 and Cyclooxygenase-2 Expression are Directly Associated with Cyclin D1 Expression in Radical Prostatectomy Specimens of Patients with Hormone-Naïve Prostate Cancer

P. Vlachostergios, D. Daliani, E. Zintzaras, 2012, Pathology & Oncology Research.

Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation

P. Vlachostergios, 2020, Journal of kidney cancer and VHL.

The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?

P. Vlachostergios, C. Papandreou, 2013, Journal of Cell Communication and Signaling.

Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis

P. Bagos, P. Kontou, P. Vlachostergios, 2022, Frontiers in Oncology.

CDK12-altered prostate cancer: Clinical features and therapeutic outcomes to standard systemic therapies, PARP inhibitors, and PD1 inhibitors

N. Agarwal, E. Antonarakis, C. Sternberg, 2019, Annals of Oncology.

Hypoxia-Inducible Factor-2-Altered Urothelial Carcinoma: Clinical and Genomic Features

P. Vlachostergios, I. Zachos, V. Tzortzis, 2022, Current oncology.

Sustained proliferation in cancer: Mechanisms and novel therapeutic targets.

Mark A Feitelson, Alan Bilsland, Amr Amin, 2015, Seminars in cancer biology.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Gloria S. Huang, Rob J. Kulathinal, C. Smythe, 2015, Seminars in cancer biology.

AFP-producing hepatoid adenocarcinoma of the stomach: a case report

P. Vlachostergios, I. Voutsadakis, C. Papandreou, 2009, Cases journal.

MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NFκB and mutant p53

P. Vlachostergios, C. Papandreou, E. Hatzidaki, 2013, Neurological research.

The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation

P. Vlachostergios, D. Daliani, A. Patrikidou, 2009, Journal of cellular and molecular medicine.

The shaping of invasive glioma phenotype by the ubiquitin–proteasome system

P. Vlachostergios, I. Voutsadakis, C. Papandreou, 2013, Cell communication & adhesion.

Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma

P. Vlachostergios, I. Voutsadakis, C. Papandreou, 2013, Cell Biology and Toxicology.

The role of ubiquitin-proteasome system in glioma survival and growth

P. Vlachostergios, I. Voutsadakis, C. Papandreou, 2013, Growth factors.

Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitors

P. Vlachostergios, 2021, Immuno-oncology technology.

Bortezomib Downregulates MGMT Expression in T98G Glioblastoma Cells

P. Vlachostergios, C. Papandreou, N. Stathakis, 2013, Cellular and Molecular Neurobiology.

ustained proliferation in cancer : Mechanisms and novel therapeutic argets ark

P. Vlachostergios, C. Boosani, S. Ashraf, 2015 .

SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy

O. Elemento, A. Sboner, H. Beltran, 2020, Molecular Cancer Therapeutics.

The Bmi-1/NF-κB/VEGF story: another hint for proteasome involvement in glioma angiogenesis?

P. Vlachostergios, C. Papandreou, 2013, Journal of Cell Communication and Signaling.

Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis

P. Vlachostergios, C. Papandreou, 2013, Archives of medical science : AMS.

Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

H. Beltran, L. Puca, P. Vlachostergios, 2018, Cold Spring Harbor perspectives in medicine.

Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives

P. Vlachostergios, C. Papandreou, 2015, Front. Oncol..

Emerging Variants of Castration-Resistant Prostate Cancer

H. Beltran, L. Puca, P. Vlachostergios, 2017, Current Oncology Reports.

Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer

C. Tsatsanis, P. Vlachostergios, K. Kamposioras, 2013, Clinical and Translational Oncology.

Loss of tumor suppressive properties of lipid metabolism enzyme CPT2 in ovarian carcinoma: Comment on “CPT2 down-regulation promotes tumor growth and metastasis through inducing ROS/NFκB pathway in ovarian cancer” by Zhang et al.

P. Vlachostergios, 2021, Translational oncology.

PI3K/AKT inhibitors in patients with refractory renal cell carcinoma: what have we learnt so far?

P. Vlachostergios, A. Molina, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer

P. Vlachostergios, S. Tagawa, J. Nauseef, 2020, Expert opinion on pharmacotherapy.

Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).

O. Smaletz, E. Antonarakis, P. Barata, 2021 .

Early mRNA Expression of Neuroendocrine Differentiation Signals Predicts Recurrence After Radical Prostatectomy: A Transcriptomic Analysis

P. Vlachostergios, C. Papandreou, V. Tzortzis, 2021, World journal of oncology.

Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival

P. Vlachostergios, V. Tzortzis, A. Karathanasis, 2022, Genes.

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer

N. Agarwal, E. Antonarakis, C. Sternberg, 2022, The Prostate.

The Role of the Small Ubiquitin-Related Modifier (SUMO) Pathway in Prostate Cancer

P. Vlachostergios, C. Papandreou, Panagiotis J. Vlachostergios, 2012, Biomolecules.

Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling

M. Rubin, O. Elemento, H. Beltran, 2019, Nature Communications.

Combined Chronic Lymphocytic Leukemia and Pancreatic Neuroendocrine Carcinoma: A Collision Tumor Variation

P. Vlachostergios, Wanhua Yang, Kaijun Huang, 2016 .

The molecular limitations of biomarker research in bladder cancer

P. Vlachostergios, B. Faltas, 2018, World Journal of Urology.

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

N. Bander, J. Osborne, P. Christos, 2021, Frontiers in Oncology.

The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer.

Z. Giannousi, P. Vlachostergios, V. Georgoulias, 2012, Lung cancer.

Gastroenterology and liver disease during COVID-19 and in anticipation of post-COVID-19 era: Current practice and future directions

P. Vlachostergios, A. Komnos, T. Zafeiridis, 2021, World journal of clinical cases.

DNA Repair Gene Polymorphisms and Susceptibility to Urothelial Carcinoma in a Southeastern European Population

P. Vlachostergios, V. Tzortzis, M. Samara, 2021, Current oncology.

The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing.

G. Sonpavde, M. Carlo, P. Vlachostergios, 2020, Cancer treatment and research communications.

Hashimoto's Thyroiditis and Kikuchi's Disease: Presentation of a Case and Review of the Literature

P. Vlachostergios, A. Saratziotis, K. Oikonomou, 2012, Case reports in otolaryngology.

A critical review on ramucirumab in the treatment of advanced urothelial cancer.

P. Vlachostergios, S. Tagawa, Charlene Thomas, 2018, Future oncology.

Elevated lactic acid is a negative prognostic factor in metastatic lung cancer.

P. Vlachostergios, K. Oikonomou, G. Apergis, 2015, Cancer biomarkers : section A of Disease markers.

Expression of Neutral Endopeptidase, Endothelin-1, and Nuclear Factor Kappa B in Prostate Cancer: Interrelations and Associations with Prostate-Specific Antigen Recurrence after Radical Prostatectomy

P. Vlachostergios, D. Daliani, E. Zintzaras, 2012, Prostate cancer.

CD10 Is Inversely Associated with Nuclear Factor-Kappa B and Predicts Biochemical Recurrence after Radical Prostatectomy

P. Vlachostergios, D. Daliani, I. Voutsadakis, 2012, Urologia Internationalis.

CD10 and Endothelin-1 are Inversely Expressed in Early Prostate Cancer and Predict Psa Failure after Radical Prostatectomy

P. Vlachostergios, D. Daliani, I. Voutsadakis, 2011 .

Acute renal infarction associated with homozygous methylenetetrahydrofolate reductase mutation C677T and IgA beta-2-glycoprotein antibodies.

P. Vlachostergios, F. Dufresne, 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Pulmonary and cutaneous nodules in an immunocompromised patient

P. Vlachostergios, K. Karamitsos, Spiros Karamagkiolis, 2011, Thorax.

Granular cell tumors of the urethra.

P. Vlachostergios, V. Tzortzis, Panagiotis J. Vlachostergios, 2023, Cancer treatment and research communications.

Fecal DNA testing for colorectal cancer screening: Molecular targets and perspectives.

P. Vlachostergios, K. Oikonomou, A. Dhaliwal, 2015, World journal of gastrointestinal oncology.

Prevention, diagnostic evaluation, management and prognostic implications of liver disease in critically ill patients with COVID-19

P. Vlachostergios, A. Komnos, I. Voulgaridi, 2023, World journal of clinical cases.

Orbital Metastasis of Breast Carcinoma

P. Vlachostergios, I. Voutsadakis, C. Papandreou, 2009, Breast cancer : basic and clinical research.

Antibody-Drug Conjugates in Bladder Cancer

P. Vlachostergios, S. Tagawa, C. Jakubowski, 2018, Bladder cancer.

Erratum to: Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

P. Vlachostergios, S. Bonanou, G. Simos, 2013, Journal of Molecular Medicine.

Bortezomib represses HIF-1α protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells

P. Vlachostergios, S. Bonanou, G. Simos, 2011, Journal of Molecular Medicine.

Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells

P. Vlachostergios, D. Daliani, I. Voutsadakis, 2012, International journal of urology : official journal of the Japanese Urological Association.

GRP78 and α2-macroglobulin are new promising targets for metastatic castrate-resistant prostate cancer treatment

P. Vlachostergios, R. Daya, R. L. Balmiki, 2015, Clinical and Translational Oncology.

Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.

O. Elemento, A. Sboner, J. Mosquera, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Rationale for co-targeting CDK4/6 and FGFR pathways in urothelial carcinoma

P. Vlachostergios, B. Faltas, K. Shohdy, 2019, Expert opinion on therapeutic targets.

Renin-Angiotensin System Single Nucleotide Polymorphisms Are Associated with Bladder Cancer Risk

P. Vlachostergios, D. Anastasiou, A. Daponte, 2021, Current oncology.

Saddle pulmonary embolism as the initial manifestation of pancreatic cancer.

P. Vlachostergios, K. Oikonomou, G. Apergis, 2015, Internal medicine.

Complete Vascular Replacement of the Infrarenal Inferior Vena Cava and Abdominal Aorta during Post-Chemotherapy Retroperitoneal Lymph Node Dissection for a Non-Seminomatous Germ Cell Tumor

P. Vlachostergios, I. Zachos, V. Tzortzis, 2023, Current oncology.

Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling

M. Rubin, O. Elemento, H. Beltran, 2019, Nature Communications.

The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.

M. Morris, W. Oh, F. Huang, 2021, Journal of Clinical Oncology.

Upper Tract Urothelial Carcinoma: A Rare Malignancy with Distinct Immuno-Genomic Features in the Era of Precision-Based Therapies

P. Vlachostergios, I. Zachos, V. Tzortzis, 2023, Biomedicines.

Bone metastases and hypercalcaemia from cutaneous squamous cell carcinoma

P. Vlachostergios, R. L. Balmiki, 2014, BMJ Case Reports.

Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition

P. Vlachostergios, I. Zachos, V. Tzortzis, 2023, F1000Research.

Radiofrequency-assisted, laparoscopic, clampless partial nephrectomy in patients with low-complexity small renal tumors: A retrospective cohort study

P. Vlachostergios, I. Zachos, C. Mamoulakis, 2023, Urology annals.

Neuroendocrine differentiation and the ubiquitin-proteasome system in cancer: Partners or enemies?

P. Vlachostergios, C. Papandreou, 2011, World Journal of Experimental Medicine.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Gloria S. Huang, Rob J. Kulathinal, C. Smythe, 2015, Seminars in Cancer Biology.

Baseline Plasma Levels of Interleukin-8 in Stage IV Non-Small-Cell Lung Cancer Patients: Relationship With Nutritional Status and Prognosis

K. Kitikidou, D. Mavroudis, V. Georgoulias, 2012, Nutrition and cancer.

Characterization of a miRNA Signature with Enhanced Diagnostic and Prognostic Power for Patients with Bladder Carcinoma

P. Vlachostergios, I. Zachos, Antonis Giakountis, 2023, International journal of molecular sciences.